LRRC37A2

Across TCGA pan-cancer cohorts, LRRC37A2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of LRRC37A2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LRRC37A2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LRRC37A2 is over-expressed in tumor, although a few such as KICH and UCEC show the opposite, repressed pattern.

LIHC, KIRC, and KICH are the cancer types where LRRC37A2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRRC37A2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.362	<.001	6	view →
KIRC	All	All	+0.173	<.001	6	view →
KICH	All	All	−0.393	<.001	4	view →
UCEC	All	All	−0.361	.002	4	view →
CHOL	Female	All	+1.453	<.001	3	view →
KIRP	All	IV	+0.545	.001	3	view →
THCA	Male	III,IV	−0.461	.018	3	view →
BLCA	Female	All	+0.371	.012	3	view →
PAAD	Male	All	+0.155	.047	2	view →
STAD	All	II,III,IV	+0.369	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

LRRC37A2–LIHC

Open the LIHC breakdown →